Clinical Trials on Fibrosis Lung in Austria

Total 2836 results

Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del

Cystic Fibrosis

Belgium, United Kingdom, Australia, Germany
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

Cystic Fibrosis

United States, United Kingdom, Canada, Australia, Germany
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

Cystic Fibrosis

United States, Canada, United Kingdom, Australia, Ireland
Aradigm Corporation
Grifols Therapeutics LLC

Completed

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

Non Cystic Fibrosis Bronchiectasis

United States, Italy, Poland, United Kingdom, France, Spain, Israel, Romania, Korea, Republic of, Australia, Canada, New Zealand, Hungary, Georgia, Former Serbia and Montenegro, Peru
AstraZeneca

Completed

Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis (MAHALE)

Non-cystic Fibrosis Bronchiectasis

United States, Canada, Denmark, Germany, Italy, United Kingdom, Vietnam, China, Spain, Korea, Republic of, Argentina, Australia, Poland, Russian Federation, Philippines, India
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

Cystic Fibrosis

United States, United Kingdom, Canada, Australia, Germany
Horizon Pharma USA, Inc.
Forest Laboratories

Completed

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Israel, New Zealand, Canada
Chris Goss
University of Washington; University of Arkansas; Harvard University; Cystic Fibrosis...

Completed

Observational Study Comparing Home to Office Spirometry (OUTREACH)

Cystic Fibrosis

United States
Proteostasis Therapeutics, Inc.

Completed

Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

Healthy Volunteer - Complete | Cystic Fibrosis - Complete

United States, Belgium, United Kingdom, France, Germany, Canada, Denmark, New Zealand, Australia
Laurent Pharmaceuticals Inc.
Cystic Fibrosis Foundation

Completed

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults (APPLAUD)

Cystic Fibrosis

United States, Australia, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

Cystic Fibrosis

United States, Germany, United Kingdom, Canada, Australia, Switzerland, France, Ireland, Belgium, Denmark, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

Cystic Fibrosis

United Kingdom, France, Germany, Australia, Switzerland, Ireland, Belgium, Denmark, Poland
University of Washington, the Collaborative Health...
Cystic Fibrosis Foundation

Completed

Saline Hypertonic in Preschoolers + CT (SHIP-CT)

Cystic Fibrosis

Spain, United States, Australia, Italy, France, Canada, Belgium, Denmark, Netherlands
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

Cystic Fibrosis

Canada, France, Germany, United Kingdom, Israel, Australia, Spain, Netherlands, Denmark, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Boehringer Ingelheim

Completed

Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Belgium, France, Germany, Italy, Netherlands, New Zealand, Portugal, Russian Federation, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Denmark, Canada, Australia, Sweden
Insmed Incorporated

Active, not recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis (ASPEN)

Non-Cystic Fibrosis Bronchiectasis

New Zealand, United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Malaysia, Mexico, Nethe... and more
University of Vienna

Recruiting

Effects of a Home-Based Exercise Intervention in Subjects With Long COVID

Post-COVID-19 Syndrome | Long COVID-19

Austria
University of Vienna

Completed

Exercise and Post-COVID/ Long-COVID: Effects of Different Training Modalities on Various Parameters in People Affected by the Sequelae of COVID-19

COVID-19 | Post-COVID-19 Syndrome | Long COVID-19

Austria
Gilead Sciences

Completed

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa (AIR-CF4)

Cystic Fibrosis | Pseudomonas Aeruginosa | Lung Infection

United States, Australia, Canada
Lassen Therapeutics 1 PTY LTD

Recruiting

A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

Thyroid Eye Disease | Pulmonary Fibrosis

Australia, New Zealand, Hong Kong
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

United States, France, United Kingdom, Germany, Spain, Belgium, Canada, Australia, Netherlands, Denmark, Czech Republic, Italy, Austria, Ireland, Sweden
Vertex Pharmaceuticals Incorporated

Completed

A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

France, Spain, Belgium, Netherlands, Australia, Italy, Czechia
Vertex Pharmaceuticals Incorporated
Moderna, Inc

Recruiting

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, United Kingdom, Australia, Canada
Medical University of Vienna
European Union

Completed

Prospective Clinical Trials on Skin Wound Healing in Young and Aged Individuals (RESOLVE)

Fibrosis | Diabetes Mellitus | Cicatrix, Hypertrophic | Age

Austria
Medical University of Vienna
XVIVO Perfusion

Recruiting

Evaluating the Addition of Hemodiafiltration to EVLP - Impact on the Regeneration of Marginal Donor Lungs

Lung Diseases

Austria
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Cystic Fibrosis

Canada, France, United Kingdom, Israel, Australia, Spain, Germany, Netherlands, Denmark, Switzerland
Medical University of Graz
Boehringer Ingelheim

Recruiting

Database for Interstitial Lung Disease

Lung Diseases, Interstitial

Austria
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation (STRIVE)

Cystic Fibrosis

United States, Canada, Australia, Ireland, France, United Kingdom, Germany, Czech Republic
Insmed Incorporated

Completed

Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection

Cystic Fibrosis

France, Poland, United Kingdom, Germany, Spain, Belgium, Bulgaria, Serbia, Denmark, Greece, Netherlands, Hungary, Ireland, Slovakia, Canada, Italy, Austria
Novartis Pharmaceuticals

Terminated

Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles

Cystic Fibrosis

United States
Medical University of Vienna

Unknown

Effect of Smoking on Ventilation-Perfusion Ratio

Lung Disease

Austria
University of Vienna

Recruiting

Impact of PD1-lymphocytes in Bronchoalveolar Lavage of Patients With Lung Cancer

Lung Cancer

Austria
Karl Landsteiner Institute for Lung Research and...

Recruiting

LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice (LALUCA)

Lung Cancer

Austria
Medical University of Vienna

Unknown

Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis

Erectile Dysfunction | Cirrhosis

Austria
Aradigm Corporation
Grifols Therapeutics LLC

Completed

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

Non Cystic Fibrosis Bronchiectasis

United States, Italy, Poland, Taiwan, United Kingdom, Germany, Spain, Israel, Romania, South Africa, Korea, Republic of, Australia, Canada, Hungary, Ireland, Latvia
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Switzerland, Italy, Czechia, Portugal, Austria, Hungary, Norway, Poland
Mukoviszidose Institut gGmbH
Assistance Publique - Hôpitaux de Paris; Novo Nordisk A/S; Mucoviscidose-ABCF2

Completed

Early Diagnosis of Diabetes Mellitus in Patients With Cystic Fibrosis

Diabetes Mellitus | Cystic Fibrosis

Germany, Austria, France, Italy
Vertex Pharmaceuticals Incorporated

Enrolling by invitation

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Cystic Fibrosis

United States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Cystic Fibrosis

United States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Cystic Fibrosis

United States, Australia, Canada, France, United Kingdom, Germany, Spain, Switzerland, Belgium, Israel, Netherlands, Denmark, Italy, Austria, Ireland, Sweden
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

Cystic Fibrosis

United States, Canada, Australia, Ireland, Germany, United Kingdom
Medical University of Vienna

Unknown

Multimodality Treatment Including Curative Resection of Advanced NSCLC

Advanced Non-small-cell Lung Cancer

Austria
Zambon SpA

Completed

Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I) (PROMIS-I)

Non Cystic Fibrosis Bronchiectasis

Australia, Greece, Israel, Italy, Portugal, Belgium, Germany, Netherlands, New Zealand, Spain, Switzerland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Denmark, Germany, Italy, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Canada, Denmark, Germany, Italy, Israel
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Rollover Study of VX-770 in Cystic Fibrosis Subjects

Cystic Fibrosis

United States, France, United Kingdom, Germany, Canada, Czech Republic, Ireland, Australia
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Italy, Czechia, Switzerland, Portugal, Austria, Hungary, Norway, Poland

Clinical Trials on Fibrosis Lung in Austria

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations